CH
Coherus Oncology, Inc.
CHRS · NASDAQ
$1.30 -3.35% (-$0.04)
1M +0.74%
Market Cap $200.9M
P/E Ratio -
Div. Yield -
ROE 181.73%
Bulios Fair Price
$1.46
12.3% upside
Trenutna cena
$1.3
Podcenjeno Poštena vrednost Precenjeno
Po podatkih Bulios Fair Price je delnica CHRS trenutno podcenjena glede na svojo tržno ceno. Kako deluje?
Bulios Fair Price je ocena poštene vrednosti delnice iz Buliosovega modela vrednotenja. Je vhod za vašo lastno analizo, ne naložbeno priporočilo. Kako deluje?
Piotroski F-Score Weak
2/9Valuation
54 /100
Fair P/B 3.30x
P/S 3.94x
EV/FFO N/A
Growth
0 /100
Declining Rev. growth 41.54%
Book val. growth N/A
EPS growth N/A
Profitability
20 /100
Weak Op. margin 307.44%
Gross margin 63.55%
FCF margin 478.87%
Quality
3 /100
Poor ROA 68.50%
ROIC 135.38%
Asset turnover 0.27x
Debt
55 /100
Moderate Int. coverage -16.74x
Debt/Equity 0.62x
Current ratio 1.77x
Stability
25 /100
Unstable EPS volatility 435.47%
Beta 0.94x
Profitable years 0
Bulios Scoring opisuje kakovost in preteklost podjetja, ne prihodnjega donosa. Visok rezultat ni nakupni signal. Izvedite več
Vprašajte StockBota o CHRS
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Dennis Lanfear
Employees
144
Headquarters
Redwood City
Prihajajoči dogodki
05 NOV.
Earnings
Upcoming earnings report